Abdul Mannan: Factor IX Prophylaxis – Can Breakthrough Bleeding Still Occur?
Abdul Mannan, Consultant Haematologist, Director Haemophilia Centre, Haematology Lab Lead at Betsi Cadwaladr University Health Board, shared a post LinkedIn:
“Can a person with haemophilia B still bleed while receiving regular factor IX treatment?
Yes. And that is a conversation worth having before a bleed occurs.
Factor IX helps blood clot. In haemophilia B, there is too little working factor IX. Regular replacement treatment helps protect against bleeding, but it cannot promise that every bleed will be prevented.
A systematic review by Lindsley and colleagues brought together 24 clinical trials and 53 observational studies involving people with haemophilia B without inhibitors who received preventive factor IX.
Here is what I would share with patients:
- Regular treatment helps reduce bleeding, but bleeds can still happen.
- Some people in the studies reported no bleeds; others experienced bleeding.
- A study average cannot tell us exactly what will happen to you.
- If you suspect a bleed, follow your care plan and contact your haemophilia team.
For clinicians, the pooled treated bleeding rate was 2.23 per year across 13 trials. Definitions and follow-up varied, so that figure needs context.
The goal is a care plan built around the person, their treatment and their experience.
How do you discuss breakthrough bleeding and treatment goals with your patients?”

More posts featuring Abdul Mannan on Hemostasis Today.
-
Nov 12, 2026, 13:04Wuhan Thrombosis Congress 2026 – Bringing Global Experts Together – ISTH
-
Nov 12, 2026, 12:55Clara N.: A United Effort to Reduce the Burden of SCD in Uganda
-
Nov 12, 2026, 12:38Sophia Delicou: Greece and Cyprus Unite to Advance Thalassaemia and Sickle Cell Care
-
Nov 12, 2026, 12:36Wolfgang Miesbach: Three Cleavages, One Key to Factor VIII Activation
-
Nov 12, 2026, 12:04Yazan Abou-Ismail: Pleasure Discussing Factor 11 Inhibitors with Nashwa Abdulsalam at Heart Rhythm TV
-
Nov 12, 2026, 11:57Javed Anees: Asundexian – A New Era in Secondary Stroke Prevention
-
Nov 12, 2026, 10:30Nancy Di Salvo: Protecting Access to IVIG and SCIG – A Call for Continued EU Recognition
-
Nov 12, 2026, 10:28Ali Hammed: Should DOAC Use Exclude Patients From Thrombolysis After Ischemic Stroke?
-
Nov 12, 2026, 10:21Aseem Kumar Tiwari: The Molecular Dimension of HLA Matching